Cargando…
Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections
Urinary tract infections (UTIs) mainly caused by Uropathogenic Escherichia coli (UPEC), are common bacterial infections. Many individuals suffer from chronically recurring UTIs, sometimes requiring long-term prophylactic antibiotic regimens. The global emergence of multi-drug resistant uropathogens...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350282/ https://www.ncbi.nlm.nih.gov/pubmed/32719668 http://dx.doi.org/10.3389/fmicb.2020.01509 |
_version_ | 1783557234041552896 |
---|---|
author | Loubet, Paul Ranfaing, Jérémy Dinh, Aurélien Dunyach-Remy, Catherine Bernard, Louis Bruyère, Franck Lavigne, Jean-Philippe Sotto, Albert |
author_facet | Loubet, Paul Ranfaing, Jérémy Dinh, Aurélien Dunyach-Remy, Catherine Bernard, Louis Bruyère, Franck Lavigne, Jean-Philippe Sotto, Albert |
author_sort | Loubet, Paul |
collection | PubMed |
description | Urinary tract infections (UTIs) mainly caused by Uropathogenic Escherichia coli (UPEC), are common bacterial infections. Many individuals suffer from chronically recurring UTIs, sometimes requiring long-term prophylactic antibiotic regimens. The global emergence of multi-drug resistant uropathogens in the last decade underlines the need for alternative non-antibiotic therapeutic and preventative strategies against UTIs. The research on non-antibiotic therapeutic options in UTIs has focused on the following phases of the pathogenesis: colonization, adherence of pathogens to uroepithelial cell receptors and invasion. In this review, we discuss vaccines, small compounds, nutraceuticals, immunomodulating agents, probiotics and bacteriophages, highlighting the challenges each of these approaches face. Most of these treatments show interesting but only preliminary results. Lactobacillus-containing products and cranberry products in conjunction with propolis have shown the most robust results to date and appear to be the most promising new alternative to currently used antibiotics. Larger efficacy clinical trials as well as studies on the interplay between non-antibiotic therapies, uropathogens and the host immune system are warranted. |
format | Online Article Text |
id | pubmed-7350282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73502822020-07-26 Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections Loubet, Paul Ranfaing, Jérémy Dinh, Aurélien Dunyach-Remy, Catherine Bernard, Louis Bruyère, Franck Lavigne, Jean-Philippe Sotto, Albert Front Microbiol Microbiology Urinary tract infections (UTIs) mainly caused by Uropathogenic Escherichia coli (UPEC), are common bacterial infections. Many individuals suffer from chronically recurring UTIs, sometimes requiring long-term prophylactic antibiotic regimens. The global emergence of multi-drug resistant uropathogens in the last decade underlines the need for alternative non-antibiotic therapeutic and preventative strategies against UTIs. The research on non-antibiotic therapeutic options in UTIs has focused on the following phases of the pathogenesis: colonization, adherence of pathogens to uroepithelial cell receptors and invasion. In this review, we discuss vaccines, small compounds, nutraceuticals, immunomodulating agents, probiotics and bacteriophages, highlighting the challenges each of these approaches face. Most of these treatments show interesting but only preliminary results. Lactobacillus-containing products and cranberry products in conjunction with propolis have shown the most robust results to date and appear to be the most promising new alternative to currently used antibiotics. Larger efficacy clinical trials as well as studies on the interplay between non-antibiotic therapies, uropathogens and the host immune system are warranted. Frontiers Media S.A. 2020-07-03 /pmc/articles/PMC7350282/ /pubmed/32719668 http://dx.doi.org/10.3389/fmicb.2020.01509 Text en Copyright © 2020 Loubet, Ranfaing, Dinh, Dunyach-Remy, Bernard, Bruyère, Lavigne and Sotto. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Loubet, Paul Ranfaing, Jérémy Dinh, Aurélien Dunyach-Remy, Catherine Bernard, Louis Bruyère, Franck Lavigne, Jean-Philippe Sotto, Albert Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections |
title | Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections |
title_full | Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections |
title_fullStr | Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections |
title_full_unstemmed | Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections |
title_short | Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections |
title_sort | alternative therapeutic options to antibiotics for the treatment of urinary tract infections |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350282/ https://www.ncbi.nlm.nih.gov/pubmed/32719668 http://dx.doi.org/10.3389/fmicb.2020.01509 |
work_keys_str_mv | AT loubetpaul alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections AT ranfaingjeremy alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections AT dinhaurelien alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections AT dunyachremycatherine alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections AT bernardlouis alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections AT bruyerefranck alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections AT lavignejeanphilippe alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections AT sottoalbert alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections |